Nanoparticle multivalency counterbalances the ligand affinity loss upon PEGylation

Journal of Controlled Release

Volumn 194, Issue , 2014, Pages 20-27

  Hennig, Robert ^a   Pollinger, Klaus ^a   Veser, Anika ^a   Breunig, Miriam ^a   Goepferich, Achim ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Active targeting; Multivalency; Nanoparticles; PEGylation; Quantum dots; Small molecules

Indexed keywords

SEMICONDUCTOR QUANTUM DOTS;

ACTIVE TARGETING; LIGAND AFFINITY; MULTIVALENCY; PEGYLATION; SMALL MOLECULES;

NANOPARTICLES;

LOSARTAN; MACROGOL; QUANTUM DOT; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANTIARRHYTHMIC AGENT; COLLOID; IMIDAZOLE DERIVATIVE; LIGAND; MACROGOL DERIVATIVE; NANOPARTICLE; TETRAZOLE DERIVATIVE;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION ASSAY; CANCER CELL LINE; CELL INTERACTION; CHEMICAL MODIFICATION; CONFOCAL MICROSCOPY; DRUG CONJUGATION; DRUG RECEPTOR BINDING; FEMALE; FLOW CYTOMETRY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PEGYLATION; PROTEIN EXPRESSION; RAT; RECEPTOR AFFINITY; ANIMAL; CHEMISTRY; COLLOID; DRUG DELIVERY SYSTEM; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CELL LINE, TUMOR; COLLOIDS; DRUG DELIVERY SYSTEMS; HUMANS; IMIDAZOLES; LIGANDS; NANOPARTICLES; POLYETHYLENE GLYCOLS; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES;

EID: 84907213359     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.07.062     Document Type: Article

References (54)

1. T.M. Allen Long-circulating (sterically stabilized) liposomes for targeted drug delivery Trends Pharmacol. Sci. 15 1994 215 220
2. W.P. Wuelfing, S.M. Gross, D.T. Miles, and R.W. Murray Nanometer gold clusters protected by surface-bound monolayers of thiolated poly(ethylene glycol) polymer electrolyte J. Am. Chem. Soc. 120 1998 12696 12697
3. H. Hatakeyama, H. Akita, and H. Harashima A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma Adv. Drug Deliv. Rev. 63 2011 152 160
4. W. Hild, K. Pollinger, A. Caporale, C. Cabrele, M. Keller, N. Pluym, A. Buschauer, R. Rachel, J. Tessmar, M. Breunig, and A. Goepferich G protein-coupled receptors function as logic gates for nanoparticle binding and cell uptake Proc. Natl. Acad. Sci. U. S. A. 107 2010 10667 10672
5. K. Pollinger, R. Hennig, M. Breunig, J. Tessmar, A. Ohlmann, E.R. Tamm, R. Witzgall, and A. Goepferich Kidney podocytes as specific targets for cyclo(RGDfC)-modified nanoparticles Small 8 2012 3368 3375
6. K. Pollinger, R. Hennig, A. Ohlmann, R. Fuchshofer, R. Wenzel, M. Breunig, J. Tessmar, E.R. Tamm, and A. Goepferich Ligand-functionalized nanoparticles target endothelial cells in retinal capillaries after systemic application Proc. Natl. Acad. Sci. U. S. A. 110 2013 6115 6120
7. X.-H. Peng, X. Qian, H. Mao, A.Y. Wang, Z.G. Chen, S. Nie, and D.M. Shin Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy Int. J. Nanomedicine 3 2008 311 321
8. S.D. Steichen, M. Caldorera-Moore, and N.A. Peppas A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics Eur. J. Pharm. Sci. 48 2012 416 427
9. W. Cai, T. Gao, H. Hong, and J. Sun Applications of gold nanoparticles in cancer nanotechnology Nanotechnol. Sci. Appl. 2008 2008
10. F.M. Veronese, O. Schiavon, G. Pasut, R. Mendichi, L. Andersson, A. Tsirk, J. Ford, G. Wu, S. Kneller, J. Davies, and R. Duncan PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity Bioconjug. Chem. 16 2005 775 784
11. R. Das, E. Baird, S. Allen, B. Baird, D. Holowka, and B. Goldstein Binding mechanisms of PEGylated ligands reveal multiple effects of the PEG scaffold Biochemistry 47 2008 1017 1030
12. S.H. Kim, J.H. Jeong, S.H. Lee, S.W. Kim, and T.G. Park PEG conjugated VEGF siRNA for anti-angiogenic gene therapy J. Control. Release 116 2006 123 129
13. X. Lin, S. Wang, Y. Jiang, Z.-J. Wang, G.-L. Sun, D.-S. Xu, Y. Feng, and L. Shen Poly(ethylene glycol)-radix Ophiopogonis polysaccharide conjugates: preparation, characterization, pharmacokinetics and in vitro bioactivity Eur. J. Pharm. Biopharm. 76 2010 230 237
14. A.P. Chapman PEGylated antibodies and antibody fragments for improved therapy: a review Adv. Drug Deliv. Rev. 54 2002 531 545
15. C.S. Fishburn The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics J. Pharm. Sci. 97 2008 4167 4183
16. A. Garcia-Bennett, M. Nees, and B. Fadeel In search of the Holy Grail: folate-targeted nanoparticles for cancer therapy Biochem. Pharmacol. 81 2011 976 984
17. F. Danhier, A. Le Breton, and V. Préat RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis Mol. Pharm. 9 2012 2961 2973
18. J. Kreuter Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv. Drug Deliv. Rev. 71 2014 2 14
19. X. Montet, M. Funovics, K. Montet-Abou, R. Weissleder, and L. Josephson Multivalent effects of RGD peptides obtained by nanoparticle display J. Med. Chem. 49 2006 6087 6093
20. R. Weissleder, K. Kelly, E.Y. Sun, T. Shtatland, and L. Josephson Cell-specific targeting of nanoparticles by multivalent attachment of small molecules Nat. Biotechnol. 23 2005 1418 1423
21. T. Dvir, M. Bauer, A. Schroeder, J.H. Tsui, D.G. Anderson, R. Langer, R. Liao, and D.S. Kohane Nanoparticles targeting the infarcted heart Nano Lett. 11 2011 4411 4414
22. S.-I. Miura, S.S. Karnik, and K. Saku Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects J. Renin Angiotensin Aldosterone Syst. 12 2011 1 7
23. W.A. Hild, M. Breunig, and A. Goepferich Quantum dots - nano-sized probes for the exploration of cellular and intracellular targeting Eur. J. Pharm. Biopharm. 68 2008 153 168
24. C.B. Murray, D.J. Norris, and M.G. Bawendi Synthesis and characterization of nearly monodisperse CdE (E = sulfur, selenium, tellurium) semiconductor nanocrystallites J. Am. Chem. Soc. 115 1993 8706 8715
25. S. Kirchhof, F.P. Brandl, N. Hammer, and A.M. Goepferich Investigation of the Diels-Alder reaction as a cross-linking mechanism for degradable poly(ethylene glycol) based hydrogels J. Mater. Chem. B 1 2013 4855
26. G. Grynkiewicz, M. Poenie, and R.Y. Tsien A new generation of Ca2 + indicators with greatly improved fluorescence properties J. Biol. Chem. 260 1985 3440 3450
27. M. de Gasparo, K.J. Catt, T. Inagami, J.W. Wright, and T. Unger International union of pharmacology. XXIII. The angiotensin II receptors Pharmacol. Rev. 52 2000 415 472
28. A. Sachinidis, Y. Ko, P. Weisser, M.K. Meyer zu Brickwedde, R. Düsing, R. Christian, A.J. Wieczorek, and H. Vetter EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells J. Hypertens. 11 1993 155 162
29. Gref, Lück, Quellec, Marchand, Dellacherie, Harnisch, Blunk, and Müller 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption Colloids Surf. B: Biointerfaces 18 2000 301 313
30. J.B. Santella, J.V. Duncia, C.L. Ensinger, M.K. VanAtten, D.J. Carini, R.R. Wexler, A.T. Chiu, P.C. Wong, and P.B. Timmermans Balanced angiotensin II receptor antagonists. III. The effects of substitution at the imidazole 5-position Bioorg. Med. Chem. Lett. 4 1994 2235 2240
31. E. Vlashi, L.E. Kelderhouse, J.E. Sturgis, and P.S. Low Effect of folate-targeted nanoparticle size on their rates of penetration into solid tumors ACS Nano 7 2013 8573 8582
32. J. Sudimack, and R.J. Lee Targeted drug delivery via the folate receptor Adv. Drug Deliv. Rev. 41 2000 147 162
33. D. Ponader, F. Wojcik, F. Beceren-Braun, J. Dernedde, and L. Hartmann Sequence-defined glycopolymer segments presenting mannose: synthesis and lectin binding affinity Biomacromolecules 13 2012 1845 1852
34. S. Miserey-Lenkei, Z. Lenkei, C. Parnot, P. Corvol, and E. Clauser A functional enhanced green fluorescent protein (EGFP)-tagged angiotensin II at(1a) receptor recruits the endogenous Galphaq/11 protein to the membrane and induces its specific internalization independently of receptor-g protein coupling in HEK-293 cells Mol. Endocrinol. 15 2001 294 307
35. A. Gabizon, A.T. Horowitz, D. Goren, D. Tzemach, F. Mandelbaum-Shavit, M.M. Qazen, and S. Zalipsky Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies Bioconjug. Chem. 10 1999 289 298
36. Y. Yang, X.-C. Xue, X.-F. Jin, L.-J. Wang, Y.-L. Sha, and Z.-J. Li Synthesis of multivalent N-acetyl lactosamine modified quantum dots for the study of carbohydrate and galectin-3 interactions Tetrahedron 68 2012 7148 7154
37. H.A. Gussin, I.D. Tomlinson, D. Cao, H. Qian, S.J. Rosenthal, and D.R. Pepperberg Quantum dot conjugates of GABA and muscimol: binding to α1β2γ2 and ρ1 GABA(A) receptors ACS Chem. Neurosci. 4 2013 435 443
38. Y. Lu, Y. Zhong, J. Wang, Y. Su, F. Peng, Y. Zhou, X. Jiang, and Y. He Aqueous synthesized near-infrared-emitting quantum dots for RGD-based in vivo active tumour targeting Nanotechnology 24 2013 135101
39. S. Hong, P.R. Leroueil, I.J. Majoros, B.G. Orr, J.R. Baker, and M.M. Banaszak Holl The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform Chem. Biol. 14 2007 107 115
40. J.H. Myung, K.A. Gajjar, J. Saric, D.T. Eddington, and S. Hong Dendrimer-mediated multivalent binding for the enhanced capture of tumor cells Angew. Chem. Int. Ed. Engl. 50 2011 11769 11772
41. L. de Miguel, M. Noiray, G. Surpateanu, B.I. Iorga, and G. Ponchel Poly(γ-benzyl-l-glutamate)-PEG-alendronate multivalent nanoparticles for bone targeting Int. J. Pharm. 460 2014 73 82
42. E.C. Dreaden, B.E. Gryder, L.A. Austin, B.A. Tene Defo, S.C. Hayden, M. Pi, L.D. Quarles, A.K. Oyelere, and M.A. El-Sayed Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells Bioconjug. Chem. 23 2012 1507 1512
43. P. Valentini, and P.P. Pompa Gold nanoparticles for naked-eye DNA detection: smart designs for sensitive assays RSC Adv. 3 2013 19181
44. I.L. Medintz, H.T. Uyeda, E.R. Goldman, and H. Mattoussi Quantum dot bioconjugates for imaging, labelling and sensing Nat. Mater. 4 2005 435 446
45. W. Cai, D.-W. Shin, K. Chen, O. Gheysens, Q. Cao, S.X. Wang, S.S. Gambhir, and X. Chen Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects Nano Lett. 6 2006 669 676
46. X. Gao, Y. Cui, R.M. Levenson, Leland W.K. Chung, and S. Nie In vivo cancer targeting and imaging with semiconductor quantum dots Nat. Biotechnol. 22 2004 969 976
47. S.J. Rosenthal, I. Tomlinson, E.M. Adkins, S. Schroeter, S. Adams, L. Swafford, J. McBride, Y. Wang, L.J. DeFelice, and R.D. Blakely Targeting cell surface receptors with ligand-conjugated nanocrystals J. Am. Chem. Soc. 124 2002 4586 4594
48. M. Amela-Cortes, V. Roullier, C. Wolpert, S. Neubauer, H. Kessler, O. Bedel, S. Mignani, and V. Marchi-Artzner Stable functionalized PEGylated quantum dots micelles with a controlled stoichiometry Chem. Commun. 47 2011 1246
49. C. Tassa, J.L. Duffner, T.A. Lewis, R. Weissleder, S.L. Schreiber, A.N. Koehler, and S.Y. Shaw Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles Bioconjug. Chem. 21 2010 14 19
50. J.E. Silpe, M. Sumit, T.P. Thomas, B. Huang, A. Kotlyar, M.A. van Dongen, M.M. Banaszak Holl, B.G. Orr, and S.K. Choi Avidity modulation of folate-targeted multivalent dendrimers for evaluating biophysical models of cancer targeting nanoparticles ACS Chem. Biol. 8 2013 2063 2071
51. M.-H. Li, S.K. Choi, T.P. Thomas, A. Desai, K.-H. Lee, A. Kotlyar, M.M. Banaszak Holl, and J.R. Baker Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting Eur. J. Med. Chem. 47 2012 560 572
52. W. Jiang, Betty Y.S. Kim, J.T. Rutka, and Warren C.W. Chan Nanoparticle-mediated cellular response is size-dependent Nat. Nanotechnol. 3 2008 145 150
53. P. Kolhar, A.C. Anselmo, V. Gupta, K. Pant, B. Prabhakarpandian, E. Ruoslahti, and S. Mitragotri Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium Proc. Natl. Acad. Sci. 110 2013 10753 10758
54. J. Wang, S. Tian, R.A. Petros, M.E. Napier, and J.M. DeSimone The complex role of multivalency in nanoparticles targeting the transferrin receptor for cancer therapies J. Am. Chem. Soc. 132 2010 11306 11313